Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Entrada Therapeutics, Inc.TRDA · Entity 2163 | Chief Medical Officer | September 01, 2023 | September 06, 2023 |
| Rezolute, Inc.RZLT · Entity 1990 | Director | November 19, 2025 | November 21, 2025 |
| Tectonic Therapeutic, Inc.AVRO · Entity 5328 | Chief Medical Officer | October 08, 2018 | October 10, 2018 |
| Xeris Biopharma Holdings, Inc.XERS · Entity 4670 | Director | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Entrada Therapeutics, Inc.
Report date September 01, 2023 · Filed September 06, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,037 |
Ending reported balance
After 2023-09-06 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2023-09-01 · Grant · Acquired 14,200 · Balance 41,330 F1: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Row 2 · 2023-09-05 · Tax withholding · Disposed 401 · Balance 40,929 F2: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs. Row 3 · 2023-09-06 · Sale · Disposed 871 · Balance 40,058 F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 4 · 2023-09-06 · Sale · Disposed 21 · Balance 40,037 F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.41 · Expires 2033-09-01 | Direct | 21,500 |
Reported balance
After 2023-09-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-09-01 · Grant · Acquired 21,500 · Balance 21,500 F5: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
F2: This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
F3: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2023.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.00 to $13.84, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.
Rezolute, Inc.
Report date November 19, 2025 · Filed November 21, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 58,576 |
Reported balance
After 2025-11-19 transaction · row 1
1 source rowRow 1 · 2025-11-19 · Grant · Acquired 21,000 · Balance 58,576 F1: Represents grant of restricted stock units which fully vest on December 1, 2026. |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.16 · Expires 2035-11-19 | Direct | 12,000 |
Reported balance
After 2025-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-11-19 · Grant · Acquired 12,000 · Balance 12,000 F2: The options fully vest on December 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units which fully vest on December 1, 2026.
F2: The options fully vest on December 1, 2026.
Tectonic Therapeutic, Inc.
Report date October 08, 2018 · Filed October 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,942 |
Reported balance
After 2018-10-08 transaction · row 1
1 source rowRow 1 · 2018-10-08 · Exercise / conversion · Acquired 2,942 · Balance 2,942 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.91 · Expires 2027-06-12 | Direct | 24,629 |
Reported balance
After 2018-10-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-10-08 · Exercise / conversion · Disposed 2,942 · Balance 24,629 F1: 25% of the shares vested on June 13, 2018 and the remaining 75% vest in equal monthly installments thereafter over a three-year period. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares vested on June 13, 2018 and the remaining 75% vest in equal monthly installments thereafter over a three-year period.
Xeris Biopharma Holdings, Inc.
Report date July 01, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,582 |
Reported balance
After 2026-07-01 transaction · row 1
1 source rowRow 1 · 2026-07-01 · Grant · Acquired 33,582 · Balance 33,582 F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.00 · Expires 2036-07-01 | Direct | 37,910 |
Reported balance
After 2026-07-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-01 · Grant · Acquired 37,910 · Balance 37,910 F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired pursuant to a restricted stock unit grant under the Company's 2018 Stock Option and Incentive Plan (the "Plan"). Each restricted stock represents a contingent right to receive one share of the Company's common stock. These shares shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
F2: These stock options were acquired pursuant to a grant under the Plan. These stock options shall vest in equal annual installments over three years, subject to continued service on the Company's Board of Directors through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 26, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 300 | $16.33 | $4,899.00 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.20 to $16.55, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 2,768 | $15.22 | $42,130.62 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,016 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:10 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 3,068 | $2.10 | $6,442.80 |
DisclosureSEC source: 0001689375-22-000033 · wf-form4_166439943270541.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,784 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 20:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 939 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · derivative · entry 6 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,625 Underlying: Common Stock · 939 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 20:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 939 | $15.09 | $14,166.79 |
DisclosureSEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 4 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 23, 2022 Filed Sep 23, 2022 20:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 939 | $2.10 | $1,971.90 |
DisclosureSEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,655 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 20:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,341 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · derivative · entry 5 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,564 Underlying: Common Stock · 3,341 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 20:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 3,341 | $15.08 | $50,393.31 |
DisclosureSEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.32, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2022 Filed Sep 23, 2022 20:57 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 3,341 | $2.10 | $7,016.10 |
DisclosureSEC source: 0001689375-22-000030 · wf-form4_166396664564604.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 106 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000026 · wf-form4_166361953637742.xml · derivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,905 Underlying: Common Stock · 106 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F3 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 106 | $15.01 | $1,591.42 |
DisclosureSEC source: 0001689375-22-000026 · wf-form4_166361953637742.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.01 to $15.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2022 Filed Sep 19, 2022 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 106 | $2.10 | $222.60 |
DisclosureSEC source: 0001689375-22-000026 · wf-form4_166361953637742.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 800 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · derivative · entry 6 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,011 Underlying: Common Stock · 800 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 800 | $15.07 | $12,053.52 |
DisclosureSEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 4 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 09, 2022 Filed Sep 12, 2022 20:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 800 | $2.10 | $1,680.00 |
DisclosureSEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 3 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,516 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,221 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · derivative · entry 5 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,811 Underlying: Common Stock · 1,221 shares Expires 2030-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F4 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | SaleCommon Stock | 1,221 | $15.13 | $18,477.76 |
DisclosureSEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 08, 2022 Filed Sep 12, 2022 20:18 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 1,221 | $2.10 | $2,564.10 |
DisclosureSEC source: 0001689375-22-000020 · wf-form4_166301390290805.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,937 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 16, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:32 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 5,172 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-097874 · tm2225276-3_4seq1.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,716 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. The RSUs were approved by the Issuer's Board of Directors on June 19, 2022 and became effective as of September 1, 2022. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2023; (ii) 25% on September 1, 2024; (iii) 25% on September 1, 2025 and (iv) the remaining 25% on September 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| July 01, 2022 Filed Jul 6, 2022 20:19 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 31,032 | $0.00 Strike: $12.00 | $0.00 |
DisclosureSEC source: 0001104659-22-077709 · tm2220515-4_4seq1.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,032 Underlying: Common stock · 31,032 shares Expires 2032-07-01 F1 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on July 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on July 1, 2026. Read SEC document |
| June 23, 2022 Filed Jun 27, 2022 21:30 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001567619-22-013407 · doc1.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-06-23 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month [until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:09 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 62,063 | $0.00 Strike: $11.57 | $0.00 |
DisclosureSEC source: 0001104659-22-030005 · tm228284-3_4seq1.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,063 Underlying: Common stock · 62,063 shares Expires 2032-03-01 F2 · derivative.exercise_date: 25% of the option shares shall vest and become exercisable on March 1, 2023, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2026. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:09 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantCommon Stock | 10,344 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-030005 · tm228284-3_4seq1.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,544 F1 · shares: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. F1 · price: Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2023; (ii) 25% on March 1, 2024; (iii) 25% on March 1, 2025 and (iv) the remaining 25% on March 1, 2026, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Read SEC document |
| December 29, 2021 Filed Dec 29, 2021 21:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | OtherStock Option (Right to Buy) · Derivative | 5,200 | $0.00 Strike: $2.10 | $0.00 |
DisclosureSEC source: 0001104659-21-154295 · tm2136524-1_4seq1.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,722 Underlying: Common Stock · 5,200 shares Expires 2030-12-01 F1 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on December 7, 2021, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 29, 2021 Filed Dec 29, 2021 21:26 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | Exercise / conversionCommon Stock | 5,200 | $2.10 | $10,920.00 |
DisclosureSEC source: 0001104659-21-154295 · tm2136524-1_4seq1.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 28, 2021 Filed Nov 1, 2021 23:00 UTC | Entrada Therapeutics, Inc. TRDA · Entity 2163 | GrantStock Option (Right to Buy) · Derivative | 72,012 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001104659-21-132478 · tm2131250-15_4seq1.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,012 Underlying: Common stock · 72,012 shares Expires 2031-10-28 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in 48 equal monthly installments commencing on October 28, 2021 (the "Vesting Start Date"), such that the option shares shall be fully vested on the four-year anniversary of the Vesting Start Date. Read SEC document |
| June 14, 2021 Filed Jul 15, 2021 01:05 UTC | Rezolute, Inc. RZLT · Entity 1990 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $12.28 | $0.00 |
DisclosureSEC source: 0001567619-21-013439 · doc1.xml · derivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-14 F1 · derivative.exercise_date: The Option will become vested and exercisable as follows: one thirty-sixth (1/36) of such Options shall vest on the first day of the month following Grant Date and each month thereafter on the first day of each month [until the Option is 100% vested. The unvested portion of the Option will not be exercisable on or after the Director's termination of Continuous Service. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 22:05 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,942 | $0.00 Strike: $0.91 | $0.00 |
DisclosureSEC source: 0000899243-18-026507 · doc4.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,629 Underlying: Common Stock · 2,942 shares Expires 2027-06-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on June 13, 2018 and the remaining 75% vest in equal monthly installments thereafter over a three-year period. Read SEC document |
| October 08, 2018 Filed Oct 10, 2018 22:05 UTC | Tectonic Therapeutic, Inc. AVRO · Entity 5328 | Exercise / conversionCommon Stock | 2,942 | $0.91 | $2,677.22 |
DisclosureSEC source: 0000899243-18-026507 · doc4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,942 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.